Carolyn Magill, Aetion CEO
May 11, 2021 06:00 AM EDT
Financing
FDA+

RWE up­start maps a new glob­al plan as in­vestors pour in the lat­est mega-round

Zachary Brennan

Senior Editor

As reg­u­la­tors con­tin­ue to re­ly more on re­al world ev­i­dence, New York-based RWE leader Ae­tion said Tues­day that it has closed a $110 mil­lion Se­ries …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times